FDA has approved Loqtorz (toripalimab-tpzi) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
